trientine has been researched along with Diabetic Angiopathies in 4 studies
Trientine: An ethylenediamine derivative used as stabilizer for EPOXY RESINS, as ampholyte for ISOELECTRIC FOCUSING and as chelating agent for copper in HEPATOLENTICULAR DEGENERATION.
TETA : An azamacrocyle in which four nitrogen atoms at positions 1, 4, 8 and 11 of a fouteen-membered ring are each substituted with a carboxymethyl group.
2,2,2-tetramine : A polyazaalkane that is decane in which the carbon atoms at positions 1, 4, 7 and 10 are replaced by nitrogens.
Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trientine treatment decreased LVM(bsa) by 5." | 2.74 | A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. ( Baker, JR; Brunton, DH; Cooper, GJ; Cowan, BR; Dissanayake, AM; Doughty, RN; Frampton, CM; Gamble, GD; Occleshaw, CJ; Phillips, AR; Poppitt, SD; Young, AA, 2009) |
| "Oral trientine treatment also caused elevated Cu excretion in humans with type 2 diabetes, in whom 6 months of treatment caused elevated left ventricular mass to decline significantly toward normal." | 1.32 | Regeneration of the heart in diabetes by selective copper chelation. ( Allen, GR; Baker, JR; Borg, TK; Boyd, PD; Brunton, DH; Chan, YK; Choong, SY; Cooper, GJ; Cowan, BR; Crossman, DJ; Dissanayake, AM; Doughty, RN; Gamble, GD; Keogh, GF; Leahy, FE; Leonard, BL; Occleshaw, CJ; Phillips, AR; Pope, AJ; Poppitt, SD; Saafi, 'L; Young, AA, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cooper, GJ | 2 |
| Young, AA | 2 |
| Gamble, GD | 2 |
| Occleshaw, CJ | 2 |
| Dissanayake, AM | 2 |
| Cowan, BR | 2 |
| Brunton, DH | 2 |
| Baker, JR | 2 |
| Phillips, AR | 2 |
| Frampton, CM | 1 |
| Poppitt, SD | 2 |
| Doughty, RN | 2 |
| Baynes, JW | 1 |
| Murray, DB | 1 |
| Choong, SY | 1 |
| Leonard, BL | 1 |
| Crossman, DJ | 1 |
| Saafi, 'L | 1 |
| Chan, YK | 1 |
| Leahy, FE | 1 |
| Keogh, GF | 1 |
| Allen, GR | 1 |
| Pope, AJ | 1 |
| Boyd, PD | 1 |
| Borg, TK | 1 |
| Cameron, NE | 1 |
| Cotter, MA | 1 |
1 trial available for trientine and Diabetic Angiopathies
| Article | Year |
|---|---|
A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study.
Topics: Adult; Aged; Blood Pressure; Body Surface Area; Chelating Agents; Creatinine; Diabetes Mellitus, Typ | 2009 |
3 other studies available for trientine and Diabetic Angiopathies
| Article | Year |
|---|---|
The metal chelators, trientine and citrate, inhibit the development of cardiac pathology in the Zucker diabetic rat.
Topics: Animals; Chelating Agents; Citric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Evalu | 2009 |
Regeneration of the heart in diabetes by selective copper chelation.
Topics: Animals; Chelating Agents; Copper; Coronary Vessels; Diabetes Mellitus, Experimental; Diabetic Angio | 2004 |
Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents.
Topics: Animals; Cell Hypoxia; Chelating Agents; Chelation Therapy; Deferoxamine; Diabetes Mellitus, Experim | 1995 |